SCHEMBL25064142

SCHEMBL25064142

CC(C)C(=O)C1CCC(CNC(=O)c2ccc(C(C)C)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.49
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
MAPK14 Q16539 6/20 0.48
EPHX1 P07099 1/20 0.48
EPHX2 P34913 1/20 0.48
ACACB O00763 1/20 0.46
LMNA P02545 1/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104788 0.90 MAPK14 (0.56) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL25064145 0.87 HDAC6 (0.49) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL24935698 0.86 ACACB (0.51) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL12090019 0.83 EPHX1 (0.67) HDAC6MAPK14EPHX1EPHX2LMNA
SCHEMBL25442206 0.81 NAMPT (0.53) MAPK14EPHX1EPHX2LMNARAB9A
SCHEMBL12089859 0.81 SMYD3 (0.53) MAPK14EPHX1EPHX2LMNARAB9A
SCHEMBL25063726 0.81 CNR2 (0.46) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL12090016 0.80 NAMPT (0.58) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL12017927 0.76 LMNA (0.58) LMNARAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL21078070 0.74 CHEK2 (0.50) HDAC6EPHX1EPHX2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054270-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054270-A1 BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF AR, SHBG, NR5A1 HDAC6 2550/4885HDAC3 3550/4885HDAC4 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.